1. Home
  2. GRYP vs MGNX Comparison

GRYP vs MGNX Comparison

Compare GRYP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRYP
  • MGNX
  • Stock Information
  • Founded
  • GRYP 2010
  • MGNX 2000
  • Country
  • GRYP United States
  • MGNX United States
  • Employees
  • GRYP N/A
  • MGNX N/A
  • Industry
  • GRYP
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRYP
  • MGNX Health Care
  • Exchange
  • GRYP Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • GRYP 87.1M
  • MGNX 87.7M
  • IPO Year
  • GRYP N/A
  • MGNX 2013
  • Fundamental
  • Price
  • GRYP $1.47
  • MGNX $1.61
  • Analyst Decision
  • GRYP Hold
  • MGNX Hold
  • Analyst Count
  • GRYP 1
  • MGNX 9
  • Target Price
  • GRYP N/A
  • MGNX $5.33
  • AVG Volume (30 Days)
  • GRYP 12.2M
  • MGNX 1.3M
  • Earning Date
  • GRYP 08-13-2025
  • MGNX 08-05-2025
  • Dividend Yield
  • GRYP N/A
  • MGNX N/A
  • EPS Growth
  • GRYP N/A
  • MGNX N/A
  • EPS
  • GRYP N/A
  • MGNX N/A
  • Revenue
  • GRYP $14,607,000.00
  • MGNX $154,050,000.00
  • Revenue This Year
  • GRYP N/A
  • MGNX N/A
  • Revenue Next Year
  • GRYP N/A
  • MGNX N/A
  • P/E Ratio
  • GRYP N/A
  • MGNX N/A
  • Revenue Growth
  • GRYP N/A
  • MGNX 255.31
  • 52 Week Low
  • GRYP $0.13
  • MGNX $0.99
  • 52 Week High
  • GRYP $2.93
  • MGNX $5.77
  • Technical
  • Relative Strength Index (RSI)
  • GRYP 64.85
  • MGNX 59.02
  • Support Level
  • GRYP $1.25
  • MGNX $1.34
  • Resistance Level
  • GRYP $1.52
  • MGNX $1.65
  • Average True Range (ATR)
  • GRYP 0.14
  • MGNX 0.11
  • MACD
  • GRYP 0.05
  • MGNX 0.04
  • Stochastic Oscillator
  • GRYP 76.65
  • MGNX 91.40

About GRYP Gryphon Digital Mining Inc Common Stock

Gryphon Digital Mining Inc is a Bitcoin mining company. Gryphon's mission is to create the world's net carbon-neutral Bitcoin miner. The company will operate a digital asset, mining operation using specialized computers equipped with application-specific integrated circuit (ASIC) chips to solve complex cryptographic algorithms in support of the Bitcoin blockchain in exchange for cryptocurrency rewards. It has vigorously acquired and develop energy assets for AI and high-performance computing (HPC) data center infrastructure. It acquire power assets, and then add electrification, infrastructure and computing power to those assets.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: